Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EBIT (2017 - 2025)

Historic EBIT for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$46.4 million.

  • Protagonist Therapeutics' EBIT fell 1198.47% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 8725.25%. This contributed to the annual value of $252.8 million for FY2024, which is 36998.14% up from last year.
  • Per Protagonist Therapeutics' latest filing, its EBIT stood at -$46.4 million for Q3 2025, which was down 1198.47% from -$42.0 million recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year EBIT high stood at $206.3 million for Q1 2024, and its period low was -$46.4 million during Q3 2025.
  • Moreover, its 5-year median value for EBIT was -$36.0 million (2023), whereas its average is -$10.8 million.
  • In the last 5 years, Protagonist Therapeutics' EBIT plummeted by 33651.57% in 2021 and then skyrocketed by 67274.65% in 2024.
  • Protagonist Therapeutics' EBIT (Quarter) stood at -$37.0 million in 2021, then increased by 1.35% to -$36.5 million in 2022, then skyrocketed by 163.12% to $23.0 million in 2023, then skyrocketed by 450.05% to $126.8 million in 2024, then crashed by 136.62% to -$46.4 million in 2025.
  • Its EBIT stands at -$46.4 million for Q3 2025, versus -$42.0 million for Q2 2025 and -$19.3 million for Q1 2025.